Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer

doi:10.19401/j.cnki.1007-3639.2017.02.012

China Oncology ›› 2017, Vol. 27 ›› Issue (2): 151-155.doi: 10.19401/j.cnki.1007-3639.2017.02.012

Previous Articles Next Articles

Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer

LU Zhouyi¹, CHEN Xiaofeng²

1. Department of Thoracic Surgery, Shanghai Pulmonary Hospital, Tongji University, Shanghai 200092, China; 2. Department of Cardio-thoracic Surgery, Huashan Hospital, Fudan University, Shanghai 200040, China

Online:2017-02-28 Published:2017-03-22
Contact: CHEN Xiaofeng E-mail: cxf3166@126.com

Abstract

Abstract: The WNT/β-catenin signaling pathway plays a critical role in cellular proliferation, differentiation and organogenesis. Aberration activation of WNT/β-catenin pathway and dysregulation of miRNA related with this pathway are involved in oncogenesis and tumor progression in primary lung cancer. Understanding the mechanism of the WNT/β-catenin signaling pathway and illuminating the interaction between miRNA and the members of this pathway may improve the perspectives of using these molecules as potential therapeutic targets for primary lung cancer. This review focused on the participation of the WNT/β-catenin signaling pathway and miRNA in lung cancer and discussion of potential targets for this malignancy therapy in the future.

Key words: Lung cancer, WNT/β-catenin signaling pathway, miRNA

LU Zhouyi, CHEN Xiaofeng. Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer[J]. China Oncology, 2017, 27(2): 151-155.

[1]	WANG Zezhou , ZHANG Yang , MO Miao , YUAN Jing , ZHOU Changming , SHEN Jie , FENG Xiaoshuang , WU Haoxuan , LI Hang , YE Ting , HU Hong , CHEN Haiquan , ZHENG Ying . Distribution of metastatic sites and survival analysis of patients with non-metastatic lung cancer at initial diagnosis based on hospital registration [J]. China Oncology, 2021, 31(9): 775-782.
[2]	LU Li, LU Renquan, SUN Jiajun, LU Ning, GUO Lin. The application of serum N-MID in auxiliary diagnosis and therapeutic effect monitoring of bone metastasis in patients with primary lung cancer [J]. China Oncology, 2021, 31(9): 838-844.
[3]	ZHU Yihui, LI Ting, HU Xichun. Clinical research progress and prospect of trastuzumab deruxtecan [J]. China Oncology, 2021, 31(8): 754-761.
[4]	LI Haizhou , ZHANG Yanwei , XU Yingjie , YANG Men , ZHANG Lei , HAN Jingjun . miR-933 inhibits proliferation, migration and invasion of lung cancer cell lines by regulation of KLF6 gene [J]. China Oncology, 2021, 31(7): 581-588.
[5]	YANG Jia , LIU Shuyuan , WANG Yingying , LI Yingfu , MA Qianli , LI Yu , WANG Yongrong , LI Chuanyin , TAN Fang . The association of polymorphisms in TNF-α gene with non-small cell lung cancer in Han population of Yunnan Province [J]. China Oncology, 2021, 31(7): 616-628.
[6]	XIE Mengqing, CHU Xiangling, ZHOU Juan, SU Chunxia. The advances in immunotherapy biomarkers of small cell lung cancer [J]. China Oncology, 2021, 31(7): 635-639.
[7]	QIAO Tingting , GE Shujing , LUO Yuan , LU Chengrong , DUAN Lianning . Mechanism of inhibition of epithelial-to-mesenchymal transition by phosphorylated H2AX in lung cancer cells [J]. China Oncology, 2021, 31(4): 277-284.
[8]	MU Lina , SU Jia , YU Shunzhang , NIU Rungui , HAN Xiaoyou , LIU Li , SHI Jianping , ZHANG Zuofeng . The control of lung cancer relating to quitting active smoking and secondary smoking: a case-control study of lung cancer in Taiyuan [J]. China Oncology, 2021, 31(4): 335-343.
[9]	YI Weili , ZHAO Wencheng , HUANG Dongning , QIN Li , WU Xintian , ZHOU Fei , WU Fengying . Analysis of immune-related adverse events and its correlation with efficacy of anti-PD-1 monotherapy in advanced non-small cell lung cancer [J]. China Oncology, 2021, 31(3): 203-211.
[10]	ZHAO Yuanyuan , ZHOU Jianying , FAN Yun , WANG Jialei , HUANG Dingzhi , LI Junling , SHI Meiqi , LIU Jiwei , YAO Yu , WU Lin , YAO Wenxiu , ZHANG Li . Advances in the treatment of BRAF V600-mutant non-small cell lung cancer [J]. China Oncology, 2021, 31(12): 1145-1152.
[11]	WU Ran , WANG Guizhen , CHENG Xin , ZHOU Guangbiao . The effects of copper ion on cell proliferation and the clinical significance of copper ion in lung cancer [J]. China Oncology, 2021, 31(11): 1072-1080.
[12]	SHEN Yujia , FU Xiaolong . Research progress of immune contexture in tumorigenesis, progression and prognostic relevance of non-small cell lung cancer [J]. China Oncology, 2021, 31(11): 1115-1125.
[13]	LIU Qian , QIAO Meng , MAO Shiqi , YANG Shuo , LIU Yiwei , ZHAO Chao , LI Xuefei , REN Shengxiang , ZHOU Caicun . Impact of metastatic organ on prognosis in extensive-stage small cell lung cancer [J]. China Oncology, 2021, 31(1): 45-51.
[14]	HE Xi, JIAO Xiaodong, ZANG Yuansheng. Clinical research progress of tumor mutational burden in EGFR-mutant advanced non-small cell lung cancer [J]. China Oncology, 2021, 31(1): 69-75.
[15]	ZHANG Cuicui, QIN Tingting, MENG Zhaoting, LI Kai. Research advances in abnormal lipid metabolism of lung cancer [J]. China Oncology, 2021, 31(1): 76-80.

Research progress on WNT/β-catenin signaling pathway and miRNA in primary lung cancer

PDF

Knowledge

Abstract

Cite this article

share this article

References

Related Articles 15

Recommended Articles

Metrics

Comments